Vivos Inc. and Exubrion Therapeutics Unite for Animal Health Innovations
In a significant development for companion animal healthcare, Vivos Inc. (OTCQB: RDGL) has announced an enhanced strategic collaboration with Exubrion Therapeutics. This partnership aims to harness targeted radioactive isotope technology, paving the way for innovative treatments addressing multiple health conditions in pets.
Broadening Collaborative Efforts
The agreement between Vivos and Exubrion marks a pivotal expansion of their collaborative efforts. The companies are focusing on several essential areas, including nurturing shared clinic relationships, streamlining licensing processes, and optimizing manufacturing capabilities. These initiatives are a natural progression from their previous work, which included device classification and the development of training modules for clinicians.
Complementary Strengths for Greater Impact
“Our companies complement one another exceptionally well,” stated Dr. Michael K. Korenko, the Chief Executive Officer of Vivos Inc. He emphasized how Exubrion’s specialization in managing osteoarthritis pain in animals, alongside Vivos’s focus on cancer therapies, enables a partnership that enhances their respective markets without conflicting competition.
Dr. Korenko also noted the importance of continuous improvement. He stated, “With only a limited number of companies exploring therapeutic applications of radioactive isotopes, collaborative innovation is vital for advancing this essential medical field.”
Shared Vision for Progress
Jennifer Kirk, Chief Executive Officer of Exubrion Therapeutics, expressed her enthusiasm regarding this partnership. “I’m excited to collaborate with the Vivos team to help further this important work,” she remarked. Together, they aim to quicken the pace of progress in the application of radioisotopes, creating a versatile platform with broad potential in veterinary medicine.
About Vivos Inc.
Vivos Inc. is recognized as a pioneering radiotherapeutic company that develops innovative isotope-based therapies for the treatment of cancer and other medical applications. The company’s flagship technologies include RadioGel for human use and IsoPet for veterinary patients. Both products are meticulously designed to ensure targeted delivery of therapeutic radiation to tumor sites while protecting the surrounding healthy tissue from exposure.
About Exubrion Therapeutics
Exubrion Therapeutics is dedicated to enhancing the quality of life for companion animals through innovative radiotherapeutic solutions. The company’s lead product, Synovetin OA, offers a minimally invasive approach to osteoarthritis treatment, targeting the core issues of the disease and providing extended relief from joint pain.
Meet the Team
Dr. Michael K. Korenko leads Vivos Inc. as CEO, where he drives the company’s strategic vision and operations. For inquiries, he can be reached via email at MKorenko@RadioGel.com. Vivos Inc. invites you to stay connected on X (formerly Twitter) @VivosIncUSA for the latest updates on their advancements in the field.
Frequently Asked Questions
What is the main focus of Vivos Inc. and Exubrion Therapeutics' collaboration?
The collaboration primarily focuses on utilizing targeted radioactive isotope technology to develop treatments for various conditions affecting companion animals.
What are the key technologies developed by Vivos Inc.?
Vivos Inc. has developed RadioGel for human applications and IsoPet specifically for veterinary use, both aimed at delivering localized therapeutic radiation.
How does Exubrion Therapeutics contribute to animal health?
Exubrion Therapeutics focuses on improving the lives of companion animals through innovative therapies, particularly in managing osteoarthritis with their product Synovetin OA.
Who leads Vivos Inc.?
Dr. Michael K. Korenko serves as the Chief Executive Officer of Vivos Inc., overseeing the strategic direction and innovation initiatives of the company.
How can I learn more about Vivos Inc.'s products?
For more information on their groundbreaking treatments and technology, you can visit Vivos Inc.'s official website at www.VivosInc.com.
